Hepatic Cytochrome P450 System Research Articles

Pharmacokinetic Optimisation of Histamine H1-Receptor Antagonist Therapy

Second-generation, relatively nonsedating histamine H1-receptor antagonists (H1-RA) are extensively used worldwide for the symptomatic treatment of allergic rhinoconjunctivitis and chronic urticaria. Information about the pharmacokinetics and pharmacodynamics of these medications, while still incomplete, is now sufficient to permit optimisation of therapy. Published pharmacokinetic and pharmacodynamic information on these H1-RA is summarised here, and areas where more data are required are delineated. Serum concentrations of most second-generation H1-RA are relatively low, and are usually measured by radioimmunoassay. After oral administration, peak concentrations are observed within 2 or 3 h. Bioavailability has not been well studied, due to the lack of intravenous formulations. Most H1-RA are metabolised in the hepatic cytochrome P450 system: terfenadine, astemizole, loratadine, azelastine, and ebastine have 1 or more active metabolites which are present in serum in higher concentrations than the respective parent compound, and therefore can be measured by high performance liquid chromatography. Cetirizine, an active metabolite of the first generation H1-receptor antagonist hydroxyzine, is not further metabolised to any great extent in vivo, and is eliminated via renal excretion. Levocabastine is also eliminated primarily by excretion. Serum elimination half-life values differ greatly from 1 H1-RA to another, and are 24 h or less for terfenadine, astemizole, loratadine, cetirizine, azelastine and ebastine, and the active metabolites of terfenadine, loratadine and ebastine. The active metabolite of azelastine (demethylazelastine) has a serum elimination half-life value of about 2 days, while that of astemizole (demethyl-astemizole) has a value of 9.5 days. From the few published studies in which the apparent volumes of distribution of the second-generation H1-RA have been calculated, it appears that tissue distribution is extensive. In children, the half-lives of H1-RA are generally shorter than are found in adults; there is no published information on the pharmacokinetics of astemizole, loratadine, azelastine, or ebastine in children. In some elderly adults, terfenadine, loratadine and cetirizine may have longer half-lives than in young healthy adults. There is little published data on the pharmacokinetics of the second-generation H1-RA in patients with impaired hepatic function. The half-life of cetirizine is prolonged in those with impaired renal function. There is a paucity of information on the pharmacokinetics of H1-RA in neonates, in pregnancy or during lactation.(ABSTRACT TRUNCATED AT 400 WORDS)

Metabolic induction of the hepatic cytochrome P450 system by chlorfenvinphos in rats

Previous studies have shown that a single oral pretreatment of rats with the organophosphorus insecticide 2-chloro-1-(2,4-dichlorophenyl)vinyl diethyl phosphate (chlorfenvinphos, CVP) afforded protection against the toxicity of a subsequent challenge with the same compound within 24 hr. This protection may be due to the reduction in brain cholinesterase inhibition caused by the decrease in plasma CVP concentration. The purpose of this study was to investigate the mechanism of the decrease in plasma CVP concentration in relation to metabolic induction. CVP was preferentially metabolized by a liver microsomal fraction with an NADPH-generating system, compared with serum or kidney subcellular fractions. A single oral 24-hr pretreatment with CVP (15 mg/kg) increased the oral LD50 of its next dosage to threefold. The same treatment also increased CVP metabolism (to 178%(, cytochrome P450 content (to 130%), cytochrome P450 reductase activity (to 130%), cytochrome b 5 content (to 121%), and cytochrome P450-linked activities such as aminopyrine demethylase (to 140%) and aniline hydroxylase (to 127%) in the hepatic microsomal fraction. A single oral 24-hr pretreatment of phenobarbital (50 mg/kg), which is known as an inducer of cytochrome P450, increased the oral LD 50 of CVP and all the related metabolic parameters listed above in an order of magnitude similar to that of CVP, although the increments induced by the phenobarbital treatment were greater than those induced by the CVP treatment. These results indicate that the increase in hepatic CVP metabolism may be due to the induction of the hepatic cytochrome P450 system caused by the single oral short-term treatment with CVP. This induction may be one of the reasons for the decrease in plasma CVP concentration which may be responsible for the reduction in toxicity of its next dosage.

Generation and detection of neoantigens in guinea pig lever slices incubated with halothane

The volatile anesthetic halothane can be biotransformed by the hepatic cytochrome P-450 system to produce a reactive intermediate, trifluoroacetyl chloride, capable of covalently binding to liver proteins. The product of this reaction, the trifluoroacetyl lysinyl moiety, can act as an epitope to alter protein antigenicity. An in vitro system has been developed to produce halothane induced neoantigens and to study conditions for formation in the liver. Liver slices, capable of halothane biotransformation, provide a viable means for mechanistic studies. Liver slices (1 cm diameter, 300 μm thick) from male Hartley guinea pigs (600–800 g) were exposed to either 1.0 or 1.7 nM halothane (media concentration) in 95% O 2/5% CO 2 for 12 h. Covalent binding was determined using 14C-halothane. Neoantigens were detected by Western immunoblot analysis using rabbit anti-trifluoroacetylated albumin antiserum. Covalent binding was detected by 1 h of incubation and increased linearly through 12 h (20.7 – 48.5 nmole equiv/mg protein). Covalent binding preceded and correlated with the appearance of neoantigens. By 12 h of incubation, five neoantigens were seen with molecular weights ranging from 51 to 97 kD. These neoantigens have molecular weights similar to those seen in vivo. Liver slices exposed to deuterated halothane, which is oxidatively metabolized to a lower extent, did not develop neoantigens. This in vitro model system can be used to examine the mechanism for covalent binding and neoantigen production in the hepatocyte.

Effect of Mycobacterium butyricum on the hepatic cytochrome P-450 system of the mouse: Influence of anti-inflammatory drug

1. M. butyricum administration to rats induces arthritis and impairment in hepatic cytochrome P-450 activity. 2. This work was performed to verify if M. butyricum administrated to mice produces similar effects on cytochrome P-450 hepatic without involvement of articular lesions. 3. We also studied the role of arachidonate metabolites in the genesis and perpetuation of hepatic injury. 4. Intraperitonal M. butyricum administration to mice increased sleeping time induced by pentobarbital and decreased both aminopyrine N-demethylase (AND) and aniline p-hydroxylase (APH) activities without producing articular inflammation. 5. Only preventative oral administration of indomethacin or dexamethasone during the week before M. butyricum injection avoided drug-metabolizing system alterations. 6. Our results suggest a possible link between arachidonate metabolites inhibited by indomethacin or dexamethasone and the genesis of cytochrome P-450 disfunction.

Riboflavin cofactor saturation of the cytochrome P450 system

Phenobarbital induction of the hepatic microsomal cytochrome P450 system in adult male rats resulted in two-fold increases in cytochrome P450 concentration and NADPH — cytochrome P450 reductase activity over untreated control rats in a two week experiment. Hepatic cytosolic glutathione transferase activity also increased. In animals taking unrestricted dietary riboflavin, the aim was to see if the increased demand for flavin cofactors imposed by induction led to a relative or non-dietary riboflavin deficiency. This was monitored by three vitamin status tests. Erythrocyte riboflavin concentration was similar in untreated and treated groups (7.5 μg per 100 ml erythrocytes), and the erythrocyte glutathione reductase test with cofactor FAD stimulation indicated similar B2 status in treated rats. However, hepatic cytosolic glutathione reductase activity was doubled in the induced animals (to 10.98±0.54 mmol NADPH oxidized per g protein per hour), and was fully saturated with cofactor in both animal groups. Glutathione reductase was also induced by phenobarbital and the enzyme was satisfying a biological role to supply reduced glutathione, for conjugation by glutathione transferase. It is proposed that the increased hepatic demand for flavin cofactors during induction was not being met by riboflavin from erythrocytes or from hepatic glutathione reductase and NADPH cytochrome P450 reductase.

Hepatic microsomal cytochrome P450 system during experimental hookworm infection

Experimental infection of golden hamsters with the hookworm, Ancylostoma ceylanicum, caused a profound decline in the hepatic microsomal cytochrome P450 content. Concomitant decrease was also noticed in aminopyrine N-demethylase and benzo[ a]pyrene hydroxylase activities. However, aniline hydroxylase activity was only marginally elevated during the infection. Microsomal markers, viz., cytochrome b 5, NADH-cytochrome- c reductase, and glucose-6-phosphatase, were not significantly altered. Hepatic tissue exhibited an accumulation of lipids, especially phospholipids, triglycerides, and cholesterol, resulting in fatty necrosis around the central vein region. Isolated hepatic microsomes showed a decrease in phosphatidylcholine content. Impairment in hepatic mixed function oxidase (MFO) activities was further confirmed by prolongation in hexobarbital sleeping time and zoxazolamine-induced paralysis. The hepatic MFO system of A. ceylanicum-infected hamsters responded qualitatively and quantitatively in a manner similar to that of control hamsters, upon stimulation with selective chemical inducers like phenobarbitone and 3-methylcholanthrene. Kinetic and in vitro substrate binding studies revealed that for aminopyrine the substrate affinity and the maximum enzyme activity ( V max) were decreased, while for aniline the binding affinity was decreased and the binding capacity was enhanced. Results indicate specific/selective impairment of the hepatic microsomal cytochrome P450 system during hookworm infection and may have many practical implications in toxicology and pharmacology.

Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation.

The hepatic cytochrome P450 system, with numerous different P450 enzymes, is characterized by its inducibility by a variety of endogenous and exogenous compounds. Specific forms of P450, exhibiting distinct but partially overlapping substrate specificities, are increased in response to a given chemical. Consequently, the rate of elimination of the inducing compound is often enhanced and the system is in this respect adaptive to changes in the environment. Transcriptional activation mechanisms for the endo- or xenobiotically controlled P450 synthesis are well documented. Here we describe a mechanism for posttranslational ligand-dependent stabilization of ethanol-inducible P450IIE1 in hepatocyte cultures. Glucagon or 8-bromoadenosine 3',5'-cyclic monophosphate causes an enhanced rate of P450IIE1 degradation in the hepatocytes as well as phosphorylation on Ser-129, a reaction which denatures the protein under in vitro conditions. Substrates for the enzyme, such as ethanol and imidazole, protect the enzyme from phosphorylation and degradation in hepatocytes but do not influence phosphorylation or degradation of phenobarbital-inducible P450IIB1. Our proposed mechanism, which remains to be shown under in vivo conditions, describes the P450 molecules as receptors for the compounds in question and might provide a way by which endo- and xenobiotics regulate their own rate of metabolism.

Coordinate Modulation of Murine Hepatic Xanthine Oxidase Activity and the Cytochrome P-450 System by Interferons

The role of xanthine oxidase (XO) in the interferon (IFN)-dependent modulation of the hepatic cytochrome P-450 system was assessed in SENCAR mice. Intraperitoneal administration of 10(4)-10(5) units of IFN-gamma resulted in dose-dependent increases in hepatic XO activities. XO activity was significantly elevated within 12 h of IFN-gamma treatment, and reached a maximum between 24-48 h, and returned to basal levels within 72-96 h. Although the kinetics of increase and decline of XO activity correlated with the loss and subsequent recovery of hepatic P-450 levels, there was no quantitative correlation between hepatic XO activity and P-450 content. Comparable results were obtained in mice pretreated with the P-450 inducer Aroclor 1254 3 days prior to IFN-gamma administration. The increases in XO activity following IFN-gamma treatment were the consequence of increases in xanthine dehydrogenase (XD), and the conversion of XD to XO. The ad libitum administration of allopurinol to IFN-gamma-treated mice reduced XO specific activity to approximately 4% of the basal activity of control mice, but did not prevent reductions in cytochrome P-450 levels or the activities of two P-450 dependent monooxygenases. Collectively, these data suggest that the reductions in the hepatic P-450 system noted after IFN administration are not a consequence of elevated XO activities.

Oxidative injury mediated by the hepatic cytochrome P-450 system in conjunction with cellular iron. Effects on the pathway of haem biosynthesis

1. Some polyhalogenated aromatic chemicals such as 2,3,7,8-tetrachloro-p-dioxin, brominated and chlorinated biphenyls, and hexachlorobenzene cause in humans, animals and hepatocyte systems a partial block in haem biosynthesis leading to accumulation and excretion of uroporphyrin, the oxidation product of the unstable biosynthetic intermediate uroporphyrinogen. 2. The involvement of reactive toxic metabolites of the halogenated chemicals has previously been suggested. The evidence presented in this paper supports a different mechanism involving chronic induction of the microsomal cytochrome P-450 system, mobilization of hepatocellular iron and associated oxidative stress. Besides oxidation of uroporphyrinogen to uroporphyrin, an inhibitor of uroporphyrinogen decarboxylase may also be formed. 3. Studies with iron-loaded mice and chicken embryo hepatocytes show that under appropriate conditions iron alone, or chemicals such as beta-naphthoflavone which induce the same cytochromes P-450 isozymes as do the chlorinated aromatics, will cause a similar uroporphyria. These findings provide an experimental model for the human disease porphyria cutanea tarda, sometimes occurring in patients with liver damage. 4. Experiments with rats and iron-loaded mice indicate that there may also be an association between the induction of uroporphyria and the development of liver tumours after administration of polyhalogenated aromatic chemicals.

Fluoroquinolones and Theophylline Toxicity: Norfloxacin

To the Editor.— Many drugs, including the new broad-spectrum fluoroquinolone anti-infective agents, are known to interfere with theophylline metabolism by the hepatic cytochrome P450 system, causing toxic reactions to theophylline. Wijnands et al1reported increases in plasma theophylline concentrations during coadministration of enoxacin (110.9%) and to a lesser degree during coadministration of ciprofloxacin (22.8%) and pefloxacin (19.6%). Although two recent pharmacokinetic studies2,3suggest that a drug-drug interaction between norfloxacin and theophylline also exists, we are not aware of any case reports of elevated theophylline levels associated with this drug in the medical literature. Three cases have been reported to the Food and Drug Administration that suggest theophylline toxic effects in patients taking norfloxacin. Each patient had a baseline steady-state theophylline level that was increased by at least 50% after starting norfloxacin therapy. A judgment was made that concomitant drugs or diseases were not likely to be responsible. All

Effect of cobalt protoporphyrin on hepatic drug-metabolizing enzymes: Specificity for cytochrome P-450

Cobaltic protoporphyrin IX (cobalt protoporphyrin) is known to cause an extensive and long-lasting depletion of hepatic cytochrome P-450 in rats, and it has been used to evaluate the role of hepatic cytochrome P-450 in xenobiotic metabolism and toxicity. To examine the specificity of cobalt protoporphyrin for hepatic cytochrome P-450, cobalt protoporphyrin was administered to rats and hamsters, and its effects on cytochrome P-450-dependent and non-P-450-dependent phase I and phase II metabolism were determined. Cobalt protoporphyrin pretreatment depleted hepatic cytochrome P-450 in both species and lowered their V max values for the hepatic microsomal metabolism of ethylmorphine, aminopyrine, ethoxyresorufin and ethoxycoumarin, without change in their K m values. In the rat, cobalt protoporphyrin treatment lowered both the V max, and the K m for microsomal metabolism of aniline. In vivo hepatic cytochrome P-450-dependent metabolism, as measured by antipyrine clearance, was decreased in both species. UDP-Glucuronyltransferase, phenolsulfotransferase and glutathione- S-transferase were unaffected, as was hepatic glutathione. Modest effects of cobalt protoporphyrin were seen on the hepatic microsomal flavoprotein mixed-function oxidase (hamster only), cytochrome P-450 reductase, cytochrome b 5, (rat only), UDPGA (rat only), and glycogen, and on blood glucose (rat). In in vivo studies with hamsters given a low dose of acetaminophen, cobalt protoporphyrin suppressed the apparent rate constants for the cytochrome P-450-dependent pathways of acetaminophen metabolism but had no effect on acetaminophen glucuronidation and sulfation. Polyacrylamide gel electrophoresis analysis indicated that cobalt protoporphyrin markedly reduced the levels of the cytochrome P-450 holoenzyme but did not alter either the content or profile of the cytochrome P-450 apoenzyme. Collectively, the data indicate that cobalt protoporphyrin shows relatively high selectivity for the hepatic cytochrome P-450 system, and support the use of this compound as a tool for resolution of the role of hepatic cytochrome P-450 in xenobiotic metabolism and toxicity.

Characterization of the hepatic cytochrome P-450 system in Atlantic salmon ( Salmo salar)

Characterization of the hepatic cytochrome P-450 system in Atlantic salmon ( Salmo salar)

Hepatic mitochondrial cytochrome P-450 system. Purification and characterization of two distinct forms of mitochondrial cytochrome P-450 from beta-naphthoflavone-induced rat liver.

We have purified two distinct isoforms of mitochondrial cytochrome P-450 from beta-naphthoflavone (beta-NF)-induced rat liver to greater than 85% homogeneity and characterized their molecular and catalytic properties. One of these isoforms showing an apparent molecular mass of 52 kDa is termed P-450mt1 and the second isoform with 54-kDa molecular mass is termed P-450mt2. Cytochrome P-450mt2 comigrates with similarly induced microsomal P-450c (the major beta-NF-inducible form) on sodium dodecyl sulfate-polyacrylamide gels and cross-reacts with polyclonal antibody monospecific for cytochrome P-450c. Cytochrome P-450mt2, however, represents a distinct molecular species since it failed to react with a monoclonal antibody to P-450c and produced V8 protease fingerprints different from P-450c. Cytochrome P-450mt1, on the other hand, did not show any immunochemical homology with P-450c or P-450mt2 as well as partially purified P-450 from control mitochondria. Electrophoretic comparisons and Western blot analysis show that both P-450mt1 and P-450mt2 are induced forms not present in detectable levels in control liver mitochondria. A distinctive property of mitochondrial P-450mt1 and P-450mt2 was that their catalytic activities could be reconstituted with both NADPH-cytochrome P-450 reductase as well as mitochondrial specific ferredoxin and ferredoxin reductase electron transfer systems, while P-450c showed exclusive requirement for NADPH-cytochrome P-450 reductase. Cytochromes P-450mt1 and P-450mt2 were able to metabolize xenobiotics like benzo(a)pyrene and dimethyl benzanthracene at rates only one-tenth with cytochrome P-450c. Furthermore, P-450mt1, P-450mt2, as well as partially purified P-450 from control liver, but not P-450c, showed varying activities for 25- and 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3. These results provide evidence for the presence of at least two distinct forms of beta-NF-inducible cytochrome P-450 in rat hepatic mitochondria.

Hepatic mitochondrial cytochrome P-450 system. Identification and characterization of a precursor form of mitochondrial cytochrome P-450 induced by 3-methylcholanthrene.

Hepatic mitoplasts from 3-methylcholanthrene-treated rats contain cytochrome P-450 which can metabolize polycyclic aromatic hydrocarbons like benzo(a)pyrene. Mitochondrial cytochrome P-450 was partially purified and reconstituted in vitro using adrenodoxin and the adrenodoxin reductase electron transfer system and [3H]benzo(a)pyrene as the substrate. A polyclonal antibody to purified microsomal P-450c (a major 3-methylcholanthrene-inducible form) inhibited the activity of mitochondrial enzyme in a concentration-dependent manner and also reacted with a 54-kDa protein on the immunoblots. A monoclonal antibody having exclusive specificity for P-450c, on the other hand, did not inhibit the aryl hydrocarbon hydroxylase activity of the mitochondrial enzyme and showed no detectable cross-reaction with the 54-kDa mitochondrial protein. Similarly, two-dimensional analysis and immunodetection using the polyclonal antibody showed distinct molecular properties of the mitochondrial enzyme different from the similarly induced microsomal P-450c with respect to the isoelectric pH. In vitro translation of free polysomes from 3-methylcholanthrene-induced liver, transport of precursor proteins by isolated mitochondria in vitro, and immunoprecipitation with the polyclonal antibody showed the presence of a 57-kDa putative precursor which is transported and processed into mature 54-kDa species. These results present evidence for the true intramitochondrial location of the P-450c-antibody reactive isoform detected in 3-methylcholanthrene-induced rat liver mitochondria.

Accidents psychiques liés à l'inhibition du catabolisme des benzodiazépines

Five clinical cases of interaction between benzodiazepines on one hand and erythromycin, troleandomycin, josamycin and cimetidine on the other hand have been analyzed. These interactions resulted in severe disorders of behaviour, amnesia (including amnesia-automatism syndrome in one case), disturbances of consciousness and withdrawal syndrome. These disorders were consecutive to inhibition of the hepatic cytochrome P-450 system. Practical means of avoiding this risk consists in limiting such drug combinations, reducing benzodiazepine dosage and, if a combined treatment is necessary, using by preference either benzodiazepines degraded by conjugation instead of oxidation, or macrolides, or anti-H2 compounds with reduced inhibitory effect on microsomes.

Hepatic cytochrome P-450 system in experimental hepatosplenic schistosomiasis: Presence of an artifact in spectrophotometric analysis

Several recent reports suggesting that the liver microsomal cytochrome P-450 system is impaired in Schistosoma mansoni infections in mice prompted a detailed investigation of the hepatic cytochrome P-450 system in murine schistosomiasis. Mice were prepared with three levels of Schistosoma mansoni infection and studied 8, 12 and 14 weeks post-exposure. Histological sections of the liver confirmed prominent granuloma formation and portal fibrosis which was dose and time dependent. Cytochrome P-450 levels appeared reduced grossly in microsomes from homogenates of infected livers, but accurate quantitation was complicated by the presence of a prominent peak at 422 nm. Ethylmorphine N-demethylase activity also appeared to be reduced in all infected animals, reaching a maximum decrease at 14 weeks of 44% of control values in the most heavily infected mice. NADPH-cytochrome c reductase activity and cytochrome b 5 levels were similarly reduced. Utilization of techniques to separate hepatocytes from granulomatous material in infected livers eliminated the 422 nm peak and reversed several of the findings made with whole-liver derived microsomes. Cytochrome P-450 levels were reduced modestly (30%) at 8 weeks in the most heavily infected mice but returned to normal values by 14 weeks. Specific ethylmorphine N-demethylase activity of isolated hepatocytes was increased at 8 weeks with a return to normal by 14 weeks. Isolated granulomata were incriminated as one possible source of the 422 nm pigment in whole-liver derived microsomes but appeared unlikely to account fully for this finding. Thus, this investigation concluded that the cytochrome P-450 system is altered by experimental murine hepatosplenic schistosomiasis, but such alterations are subtle in nature and unlikely to contribute in major fashion to the observed changes in drug disposition.

Effects of in vivo administration of detergents on the hepatic microsomal cytochrome P-450 system in rat.

The influence of in vivo administration of detergents on the hepatic microsomal cytochrome P-450 system was studied in rat. Male Wistar rats were administered detergents, Emulgen 913 (50 mg or 100 mg kg-1 of body weight (B.W.], or sodium dodecylsulfate (SDS, 25 mg or 50 mg kg-1 of B.W.) intraperitoneally once a day for 3 days. Cytochrome P-450 content in liver microsomes was significantly decreased to 85% and 73% of control by the administration of 50 mg or 100 mg Emulgen, respectively, but the microsomal protein concentration was not changed by these administrations. The content of cytochrome P-450 was also reduced to 76% and 70% of control by the administration of 25 mg or 50 mg SDS/kg of B.W., respectively. The total hydroxylation activity (the sum of omega- and (omega-1)-hydroxylase activity) of laurate almost paralleled the decrease in cytochrome P-450 in detergent-treated rats. However, the omega/omega-1-hydroxylation ratio was not changed. These results suggest that the administration of these detergents lowered the level of cytochrome P-450 species catalyzing omega- and (omega-1)-hydroxylation of laurate to a similar extent. On the other hand, aminopyrine N- and p-nitroanisole O-demethylation activities in Emulgen 913-treated rats was decreased while those in SDS-treated rats did not change, though the content of cytochrome P-450 was decreased by both administrations. Thus, it was demonstrated that the livers of rats responded to exogenous detergents in different manners.

Induction of the hepatic microsomal cytochrome P-450 system by trialkyl phosphorothioates in rats

Single i.p. doses of O,O,O-triethyl phosphorothioate [OOO-Et(S)], one of the suicide substrates for cytochrome P-450, caused a rapid increase of NADPH-cytochrome c reductase activity in rat liver microsomes. The increase was dose dependent but did not coincide with the recovery from the inhibition of drug-metabolizing activities. There was no change of K m value of the reductase in the induced state. The co-administration of cycloheximide repressed the stimulatory effect of OOO-Et(S), suggesting that a de novo synthesis of enzyme protein may be responsible for the increase in activity. Of four homologous tri- n-alkyl esters tested, the triethyl compound was the most effective at 24 and 48 hr after administration. Triethyl phosphate, the oxygen analog of OOO-Et(S), also caused an increase of the reductase activity, but carbon disulfide had no influence on this activity. Although O,O,S-triethyl phosphorodithioate [OOS-Et(S)] and its n-alkyl homologs also caused the inhibition of drug-metabolizing activities and the increase of the reductase activity, the recovery and the stimulation of enzyme activity were different from that of O,O,O-tri- n-aklyl phosphorothioates.

Famotidine: a notable lack of drug interactions.

Cimetidine, an H2-receptor antagonist, has been shown to inhibit the oxidative metabolism of several drugs by interacting with the hepatic cytochrome P450 system, which is involved in phase-I oxidative drug metabolism. Ranitidine, another H2-receptor antagonist, has been shown to have an extremely low level of interaction with the cytochrome P450 system. The potential of famotidine, a new H2-receptor antagonist with a guanylthiazole ring structure, to interact with the cytochrome P450 system has been extensively evaluated. Many of the studies used cimetidine and/or ranitidine as active controls. In vitro studies investigated the potential effects of famotidine coadministration on aminopyrine and diazepam demethylase activity, disturbances of P450 spectra, and effects on the metabolism of specific substrates such as deethylation of 7-ethoxycoumarin and demethylation of benzphetamine. Famotidine and ranitidine showed negligible interaction with the cytochrome P450 reactions studied, in contrast to the rather marked interaction demonstrated with cimetidine. Several in vivo animal studies investigated the effect of famotidine on hexobarbital sleeping time; plasma concentrations of diazepam, warfarin, and propranolol; antipyrine elimination kinetics; and warfarin prothrombin complex activity. Famotidine and ranitidine demonstrated either no evidence or minimal evidence of interaction with cytochrome P450 functions, in direct contrast to marked interactions produced by cimetidine. Human studies investigated the potential of an interaction with the coadministration of famotidine and aminopyrine, antipyrine, diazepam, theophylline, phenytoin, and warfarin. Coadministration of famotidine had no effect on the pharmacokinetic variables of theophylline, diazepam, desmethyldiazepam, and phenytoin and no effect on the half-life of antipyrine and aminopyrine or on the prothrombin time ratios associated with warfarin therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Inhibitory and inducing effects of denzimol on carbamazepine metabolism in the rat.

In vivo and in vitro alterations in carbamazepine (CBZ) metabolism and the extent of enzyme induction of the hepatic cytochrome P-450 system after chronic oral denzimol to rats were evaluated. No effect on drug-metabolizing enzymes was detected for this new anticonvulsant drug at a dose of 15 mg/kg, which is just above the anticonvulsive dose. At higher doses (60 mg/kg) denzimol significantly raised the hepatic cytochrome P-450 content, enhanced CBZ clearance and tend to shorten its elimination t1/2 and that of its active metabolite. These results, combined with those of a previous study showing impairment of CBZ metabolism after single doses of denzimol, suggest that the drug may have either inductive or inhibitory effects on microsomal mixed-function oxidase activity in the rat, depending on the dose and schedule of treatment.